Medicure (TSXV:MPH) ROCE % : -30.66% (As of Dec. 2023)

View and export this data going back to 1999. Start your Free Trial

What is Medicure ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Medicure's annualized ROCE % for the quarter that ended in Dec. 2023 was -30.66%.

Medicure ROCE % Historical Data

The historical data trend for Medicure's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicure ROCE % Chart

Medicure Annual Data

Trend

May14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-33.41

-25.96

-3.46

6.58

-4.21

Medicure Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															16.16	10.94	5.58	1.66	-30.66

Medicure ROCE % Calculation

Medicure's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-0.877	/	( ( (29.898 - 8.39)	+	(28.059 - 7.934) )	/ 2 )
	=	-0.877	/	( (21.508	+	20.125)	/ 2 )
	=	-0.877	/	20.8165
	=	-4.21 %

Medicure's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-6.48	/	( ( (28.845 - 6.704)	+	(28.059 - 7.934) )	/ 2 )
	=	-6.48	/	( ( 22.141	+	20.125 )	/ 2 )
	=	-6.48	/	21.133
	=	-30.66 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Medicure (TSXV:MPH) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Medicure ROCE % Related Terms

Thank you for viewing the detailed overview of Medicure's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Medicure (TSXV:MPH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medicure Inc (TSXV:MPH) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

MCUJF:USA NGQ1:Germany

Address

2 - 1250 Waverley Street, Winnipeg, MB, CAN, R3T 6C6

Website

https://www.medicure.com

Medicure Inc is a biopharmaceutical company. It is involved in the research, clinical development, and commercialization of human therapeutics for the United States hospital market. Further, it also operates a specialty pharmacy in the United States of America. The company's present focus is the sale and marketing of its cardiovascular products, AGGRASTAT, ZYPITAMAG, and developing its e-commerce and mail order pharmaceutical business. The company operates in two segments namely, Marketing and distribution of commercial products and, Retail and mail order pharmacy. The majority of the company's revenue is generated from the marketing and distribution of the commercial products segment.

Medicure (TSXV:MPH) Headlines

No Headlines